Zhenming Shun Selected Research

Ovarian Neoplasms (Ovarian Cancer)

2/2014

Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhenming Shun Research Topics

Disease

1	Neutropenia 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Lymphopenia (Lymphocytopenia) 01/2022
1	Primary Myelofibrosis (Myelosclerosis) 07/2017
1	Wernicke Encephalopathy (Wernicke's Encephalopathy) 07/2017
1	Disease Progression 02/2014
1	Fallopian Tube Neoplasms 02/2014
1	Ovarian Neoplasms (Ovarian Cancer) 02/2014
1	Lung Neoplasms (Lung Cancer) 07/2010
1	Adenocarcinoma 07/2010
1	Adenocarcinoma of Lung 07/2010

Drug/Important Bio-Agent (IBA)

2	PlatinumIBA 02/2014 - 07/2010
2	afliberceptIBA 02/2014 - 07/2010
1	cabazitaxel FDA Link 01/2022
1	Prostate-Specific Antigen (Semenogelase)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	fedratinibIBA 07/2017
1	ruxolitinibIBA 07/2017
1	Topotecan (Hycamtin)FDA LinkGeneric 02/2014
1	liposomal doxorubicin (Doxil)FDA Link 02/2014
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2010
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2010
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2010
1	Recombinant Fusion ProteinsIBA 07/2010

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2022 - 07/2010
1	Castration 01/2022
1	Therapeutics 07/2010